MX2022010230A - Complejos de anillos macrociclicos de pentaaza que poseen biodisponibilidad oral. - Google Patents
Complejos de anillos macrociclicos de pentaaza que poseen biodisponibilidad oral.Info
- Publication number
- MX2022010230A MX2022010230A MX2022010230A MX2022010230A MX2022010230A MX 2022010230 A MX2022010230 A MX 2022010230A MX 2022010230 A MX2022010230 A MX 2022010230A MX 2022010230 A MX2022010230 A MX 2022010230A MX 2022010230 A MX2022010230 A MX 2022010230A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- substituted
- formula
- alkyl
- oral bioavailability
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic System
- C07F13/005—Compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic System
- C07F1/08—Copper compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
- C07F15/02—Iron compounds
- C07F15/025—Iron compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
- C07F15/04—Nickel compounds
- C07F15/045—Nickel compounds without a metal-carbon linkage
Abstract
Los aspectos de la presente descripción se refieren a compuestos que tienen mejor biodisponibilidad oral. Un complejo de metal de transición incluye un metal de transición coordinado por un macrociclo que comprende el anillo macrocíclico de 15 miembros de pentaaza que corresponde a la Fórmula A y dos ligandos axiales que tienen la fórmula -OC(O)X1. (Fórmula A) cada uno de los dos ligandos axiales tiene la fórmula -OC(=O)X1, donde cada X1 es fenilo independientemente sustituido o no sustituido o -C(-X2)(-X3)(-X4); cada X2 es fenilo independientemente sustituido o no sustituido o alquilo sustituido o no sustituido; cada X3 es independientemente hidrógeno, hidroxilo, alquilo, amino, -X5C(O)R13 donde X5 es NH u O, y R13 es alquilo C1-C18, arilo sustituido o no sustituido o aralquilo C1-C18, o -OR14, donde R14 es alquilo C1-C18, arilo sustituido o no sustituido o aralquilo C1-C18, o junto con X4 es =O; y cada X4 es independientemente hidrógeno o junto con X3 es =O.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562203761P | 2015-08-11 | 2015-08-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022010230A true MX2022010230A (es) | 2022-09-19 |
Family
ID=57984526
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018001605A MX2018001605A (es) | 2015-08-11 | 2016-08-11 | Complejos de anillos macrocíclicos de pentaaza que poseen biodisponibilidad oral. |
MX2022010230A MX2022010230A (es) | 2015-08-11 | 2018-02-07 | Complejos de anillos macrociclicos de pentaaza que poseen biodisponibilidad oral. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018001605A MX2018001605A (es) | 2015-08-11 | 2016-08-11 | Complejos de anillos macrocíclicos de pentaaza que poseen biodisponibilidad oral. |
Country Status (29)
Country | Link |
---|---|
US (5) | US10597415B2 (es) |
EP (2) | EP3334744B1 (es) |
JP (3) | JP7041959B2 (es) |
KR (1) | KR20180064380A (es) |
CN (3) | CN113416170A (es) |
AU (3) | AU2016306568B2 (es) |
CA (1) | CA2994845A1 (es) |
CL (1) | CL2018000371A1 (es) |
CO (1) | CO2018002544A2 (es) |
CY (1) | CY1123960T1 (es) |
DK (1) | DK3334744T3 (es) |
EA (1) | EA201890471A1 (es) |
ES (1) | ES2807528T3 (es) |
HK (1) | HK1257313A1 (es) |
HR (1) | HRP20201092T1 (es) |
HU (1) | HUE049926T2 (es) |
IL (3) | IL297735B1 (es) |
LT (1) | LT3334744T (es) |
MX (2) | MX2018001605A (es) |
MY (1) | MY196401A (es) |
PH (1) | PH12018500296A1 (es) |
PL (1) | PL3334744T3 (es) |
PT (1) | PT3334744T (es) |
RS (1) | RS60558B1 (es) |
SG (1) | SG10202002859QA (es) |
SI (1) | SI3334744T1 (es) |
UA (1) | UA126788C2 (es) |
WO (1) | WO2017027728A1 (es) |
ZA (2) | ZA201801546B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2056675B1 (en) | 2006-10-12 | 2019-01-09 | Galera Labs, LLC | Methods of treating oral mucositis |
JP6267638B2 (ja) | 2011-09-26 | 2018-01-24 | ガレラ・ラブス・リミテッド・ライアビリティ・カンパニーGalera Labs, Llc | 疾患の治療方法 |
SG10202002859QA (en) | 2015-08-11 | 2020-05-28 | Galera Labs Llc | Pentaaza macrocyclic ring complexes possessing oral bioavailability |
CN109906081A (zh) | 2016-09-01 | 2019-06-18 | 加莱拉实验室有限责任公司 | 利用五氮杂大环络合物和抗坏血酸类化合物的联合癌症疗法 |
AU2018221043A1 (en) | 2017-02-15 | 2019-09-12 | Galera Labs, Llc | Pentaaza macrocyclic ring complexes for local intestinal delivery |
IL269915B (en) | 2017-04-13 | 2022-09-01 | Galera Labs Llc | Cancer immunotherapy combined with a macrocyclic ring pentase complex |
IL305082A (en) * | 2017-04-13 | 2023-10-01 | Galera Labs Llc | Cancer immunotherapy combined with a macrocyclic ring pentase complex |
JP2022551494A (ja) * | 2019-10-10 | 2022-12-09 | ガレラ・ラブス・リミテッド・ライアビリティ・カンパニー | マンガン含有配位錯体の水性製剤の製造方法、製剤および処置方法 |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4001212A (en) | 1973-10-03 | 1977-01-04 | E. I. Du Pont De Nemours And Company | Macrocyclic polyamines |
US3930867A (en) | 1974-01-07 | 1976-01-06 | E. I. Du Pont De Nemours And Company | Macrocyclic polyamines as sensitizers for silver halide emulsions |
JPS61226751A (ja) | 1985-03-30 | 1986-10-08 | Konishiroku Photo Ind Co Ltd | ハロゲン化銀写真感光材料用処理液及びその処理方法 |
US5096724A (en) | 1988-06-03 | 1992-03-17 | Aquanautics Corporation | Methods, compositions, and systems for ligand extraction |
GB9001245D0 (en) | 1990-01-19 | 1990-03-21 | Salutar Inc | Compounds |
KR0145953B1 (ko) | 1991-07-19 | 1998-08-17 | 제임스 클리프튼 보올딩 | 슈퍼옥사이드의 불균화촉매로서 효과적인 질소를 포함하는 마크로사이클 릭리간드의 망간착물 |
CA2072934C (en) * | 1991-07-19 | 2007-08-28 | Karl William Aston | Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
US6204259B1 (en) | 1993-01-14 | 2001-03-20 | Monsanto Company | Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
EP0756495A1 (en) | 1994-04-22 | 1997-02-05 | Monsanto Company | Diagnostic image analysis with metal complexes |
US6245758B1 (en) | 1994-05-13 | 2001-06-12 | Michael K. Stern | Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor |
US6525041B1 (en) | 1995-06-06 | 2003-02-25 | Pharmacia Corporation | Manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
BR9610241A (pt) | 1995-08-17 | 1999-06-29 | Monsanto Co | Processos para análise de imagem de diagnóstico utilizando bioconjgados de complexos de metal de ligandos macrocíclicos contendo nitrogênio |
US5976498A (en) | 1995-08-17 | 1999-11-02 | Neumann; William L. | Methods of diagnostic image analysis using metal complexes of nitrogen-containing macrocyclic ligands |
US20060270639A1 (en) | 1997-06-20 | 2006-11-30 | Daniela Salvemini | Combinations of superoxide dismutase mimetics and nonsteroidal analgesic/anti-inflammatory drugs |
US6180620B1 (en) | 1997-06-20 | 2001-01-30 | G.D. Searle & Co. | Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals |
US6214817B1 (en) | 1997-06-20 | 2001-04-10 | Monsanto Company | Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity |
US20020128248A1 (en) | 1997-06-20 | 2002-09-12 | Metaphore Pharmaceuticals, Inc | SODm therapy for prevention and/or treatment of inflammatory disease |
US20050171198A1 (en) | 1997-06-20 | 2005-08-04 | Metaphore Pharmaceuticals, Inc. | SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease |
EP1045851B1 (en) | 1997-11-03 | 2003-04-23 | Duke University | Substituted porphyrins |
GB9817845D0 (en) | 1998-08-17 | 1998-10-14 | Glaxo Group Ltd | Chemical compounds |
US6040330A (en) | 1999-01-08 | 2000-03-21 | Bionumerik Pharmaceuticals, Inc. | Pharmaceutical formulations of taxanes |
EP1185312B1 (en) | 1999-05-27 | 2005-03-23 | Monsanto Company | Biomaterials modified with superoxide dismutase mimics |
US6448239B1 (en) | 1999-06-03 | 2002-09-10 | Trustees Of Princeton University | Peroxynitrite decomposition catalysts and methods of use thereof |
AU3679801A (en) | 2000-02-08 | 2001-08-20 | Rice University | Optically-active nanoparticles for use in therapeutic and diagnostic methods |
US7279160B2 (en) | 2000-05-02 | 2007-10-09 | The Uab Research Foundation | Combinations of DR5 antibodies and other therapeutic agents |
US20020072512A1 (en) | 2000-12-08 | 2002-06-13 | Metaphore Pharmaceuticals, Inc | Method of preventing and treating HIV-mediated central nervous system damage |
US20050175580A1 (en) | 2001-01-05 | 2005-08-11 | Daniela Salvemini | Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines |
DE60233317D1 (de) | 2001-01-19 | 2009-09-24 | Nat Jewish Med & Res Center | Medikament zum schutz in der radiotherapie |
WO2002058686A2 (en) | 2001-01-26 | 2002-08-01 | Metaphore Pharmaceuticals, Inc. | Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes |
US20040137638A1 (en) | 2002-03-04 | 2004-07-15 | Slomczynska Urszula J. | Chromatography of metal complexes |
WO2002071054A1 (en) * | 2001-03-02 | 2002-09-12 | Metaphore Pharmaceuticals, Inc. | Chromatography of metal complexes |
WO2002100395A1 (en) | 2001-06-08 | 2002-12-19 | Genzyme Corporation | Bismuth salts of anti-oxidants and radical scavengers for prevention and treatment of mucous membrane ulcers |
US20040132706A1 (en) | 2001-10-05 | 2004-07-08 | Daniela Salvemini | Composition comprising a catalyst for the dismutation of superoxide and use of the composition for preventing and treating hypotension |
BRPI0213846B8 (pt) | 2001-11-01 | 2021-05-25 | Uab Research Foundation | composição que compreende um anticorpo que liga especificamente uma dr5 do receptor de trail e um ou mais agentes terapêuticos |
JP2005530738A (ja) | 2002-04-16 | 2005-10-13 | アイシス・イノヴェイション・リミテッド | 組織障害の予防及び/又は治療のためのクルクミン |
US20050101581A1 (en) | 2002-08-28 | 2005-05-12 | Reading Christopher L. | Therapeutic treatment methods 2 |
WO2005042718A2 (en) | 2003-10-31 | 2005-05-12 | Metaphore Pharmaceuticals, Inc. | Compositions and methods for treating, preventing, reversing and inhibiting pain |
WO2005070126A2 (en) | 2004-01-08 | 2005-08-04 | The Regents Of The University Of Colorado | Methods and compositions for treating human diseases and wounds with ucp and fas inhibitors |
GB0412893D0 (en) * | 2004-06-10 | 2004-07-14 | Univ Hull | Novel antiviral macrocycle derivatives and metal complexes, incorporating bridged macrocycles |
US8217166B2 (en) | 2005-05-05 | 2012-07-10 | Galera Therapeutics, Llc | Polyethylene glycolated superoxide dismutase mimetics |
WO2006083508A2 (en) | 2005-01-10 | 2006-08-10 | Metaphore Pharmaceuticals Inc. | Combinations of superoxide dismutase mimetics and nonsteroidal analgesic/anti-inflammatory drugs |
WO2006078713A2 (en) | 2005-01-19 | 2006-07-27 | Metaphore Pharmaceuticals, Inc. | Methotrexate combinations for treating inflammatory diseases |
CA2601575A1 (en) | 2005-03-31 | 2006-10-05 | Schering Corporation | Spirocyclic thrombin receptor antagonists |
US20100158857A1 (en) | 2006-05-23 | 2010-06-24 | University Of Utah Research Foundation | Compositions and methods for the inhibition of endothelial nitric oxide synthase activity |
US20080139525A1 (en) | 2006-08-31 | 2008-06-12 | The Brigham And Women's Hospital, Inc. | Antioxidant therapies |
EP2056675B1 (en) | 2006-10-12 | 2019-01-09 | Galera Labs, LLC | Methods of treating oral mucositis |
WO2009065059A2 (en) * | 2007-11-14 | 2009-05-22 | Kereos, Inc. | Super-oxide dismutase mimetics |
WO2009111294A1 (en) | 2008-02-29 | 2009-09-11 | Eagle Pharmaceuticals, Inc. | Topotecan ready to use solutions |
CA2720846A1 (en) | 2008-04-15 | 2009-11-05 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
WO2009143454A2 (en) | 2008-05-22 | 2009-11-26 | Kereos, Inc. | Combination antitumor therapy |
KR20130049775A (ko) | 2010-03-12 | 2013-05-14 | 애브비 바이오테라퓨틱스 인크. | Ctla4 단백질 및 이의 용도 |
JP6267638B2 (ja) | 2011-09-26 | 2018-01-24 | ガレラ・ラブス・リミテッド・ライアビリティ・カンパニーGalera Labs, Llc | 疾患の治療方法 |
US9238659B2 (en) | 2012-11-19 | 2016-01-19 | The University Of Hong Kong | Method of using binuclear gold (I) compounds for cancer treatment |
SG10202002859QA (en) | 2015-08-11 | 2020-05-28 | Galera Labs Llc | Pentaaza macrocyclic ring complexes possessing oral bioavailability |
BR112018072560A2 (pt) | 2016-05-03 | 2019-02-19 | Galera Labs, Llc | terapia de combinação para tratamento do câncer |
-
2016
- 2016-08-11 SG SG10202002859QA patent/SG10202002859QA/en unknown
- 2016-08-11 CN CN202110688812.XA patent/CN113416170A/zh active Pending
- 2016-08-11 HU HUE16835928A patent/HUE049926T2/hu unknown
- 2016-08-11 MX MX2018001605A patent/MX2018001605A/es unknown
- 2016-08-11 US US15/751,495 patent/US10597415B2/en active Active
- 2016-08-11 UA UAA201802349A patent/UA126788C2/uk unknown
- 2016-08-11 PT PT168359289T patent/PT3334744T/pt unknown
- 2016-08-11 ES ES16835928T patent/ES2807528T3/es active Active
- 2016-08-11 PL PL16835928T patent/PL3334744T3/pl unknown
- 2016-08-11 KR KR1020187006846A patent/KR20180064380A/ko not_active Application Discontinuation
- 2016-08-11 IL IL297735A patent/IL297735B1/en unknown
- 2016-08-11 CN CN201680058867.XA patent/CN108350009B/zh active Active
- 2016-08-11 MY MYPI2018700525A patent/MY196401A/en unknown
- 2016-08-11 LT LTEP16835928.9T patent/LT3334744T/lt unknown
- 2016-08-11 JP JP2018506866A patent/JP7041959B2/ja active Active
- 2016-08-11 DK DK16835928.9T patent/DK3334744T3/da active
- 2016-08-11 EP EP16835928.9A patent/EP3334744B1/en active Active
- 2016-08-11 AU AU2016306568A patent/AU2016306568B2/en active Active
- 2016-08-11 RS RS20200860A patent/RS60558B1/sr unknown
- 2016-08-11 CA CA2994845A patent/CA2994845A1/en active Pending
- 2016-08-11 WO PCT/US2016/046599 patent/WO2017027728A1/en active Application Filing
- 2016-08-11 CN CN202110688814.9A patent/CN113402560A/zh active Pending
- 2016-08-11 EP EP20168046.9A patent/EP3738967A1/en active Pending
- 2016-08-11 SI SI201630852T patent/SI3334744T1/sl unknown
- 2016-08-11 EA EA201890471A patent/EA201890471A1/ru unknown
- 2016-08-25 US US15/246,788 patent/US9738669B2/en active Active
- 2016-08-25 US US15/246,830 patent/US9738670B2/en active Active
-
2018
- 2018-02-04 IL IL257346A patent/IL257346B/en unknown
- 2018-02-07 MX MX2022010230A patent/MX2022010230A/es unknown
- 2018-02-09 PH PH12018500296A patent/PH12018500296A1/en unknown
- 2018-02-09 CL CL2018000371A patent/CL2018000371A1/es unknown
- 2018-03-06 ZA ZA2018/01546A patent/ZA201801546B/en unknown
- 2018-03-09 CO CONC2018/0002544A patent/CO2018002544A2/es unknown
- 2018-12-21 HK HK18116470.5A patent/HK1257313A1/zh unknown
-
2020
- 2020-03-04 ZA ZA2020/01373A patent/ZA202001373B/en unknown
- 2020-03-09 US US16/812,740 patent/US11066433B2/en active Active
- 2020-07-13 HR HRP20201092TT patent/HRP20201092T1/hr unknown
- 2020-07-21 CY CY20201100665T patent/CY1123960T1/el unknown
- 2020-12-15 AU AU2020289730A patent/AU2020289730B2/en active Active
-
2021
- 2021-07-19 US US17/378,852 patent/US20210347796A1/en active Pending
- 2021-10-25 IL IL287546A patent/IL287546B2/en unknown
- 2021-10-28 JP JP2021176312A patent/JP2022023183A/ja active Pending
-
2023
- 2023-02-10 AU AU2023200738A patent/AU2023200738A1/en active Pending
- 2023-10-27 JP JP2023184571A patent/JP2024012401A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022010230A (es) | Complejos de anillos macrociclicos de pentaaza que poseen biodisponibilidad oral. | |
PH12021551167A1 (en) | New heterocyclic compounds | |
PH12015501860B1 (en) | Dispiropyrrolidine derivative | |
MX359199B (es) | Compuestos de tetrazolinona y su uso como plaguicidas. | |
SG11201805286RA (en) | α,β-UNSATURATED AMIDE COMPOUND | |
SA515361086B1 (ar) | Fasn مركبات وتركيبات جديدة لتثبيط | |
AU2016277367A8 (en) | Aryl sulfonohydrazides | |
RS54730B1 (sr) | Inhibitori beta sekretaze | |
JO3318B1 (ar) | مثبطات bace | |
MX2017016030A (es) | Derivado de dihidropirrolopirazol sustituido. | |
MX2016005993A (es) | Anfifilos biscationicos y triscationicos como agentes antimicrobianos. | |
RU2012148909A (ru) | Новый синтез соединений тиазолидиндиона | |
WO2014108795A3 (en) | An improved process for the preparation of chiral diol sulfones and statins | |
CR20220117A (es) | Compuestos heterocíclicos | |
PH12018501642B1 (en) | Method for preparing pyrrolo[3,2-d]pyrimidine compound, and intermediates thereof | |
MX2017014661A (es) | Proceso para la preparacion de triazinas. | |
IN2014DN07996A (es) | ||
MX2015015841A (es) | Compuestos de fenoxietil dihidro-1h-isoquinolina. | |
AU2024202337A1 (en) | Process for preparing methoxy methyl pyridine dicarboxylate | |
WO2017168447A9 (en) | A cyclic compounds and process for the preparation thereof | |
EP4249471A3 (en) | Pharmaceutical composition of a nitrogen-containing compound or salt thereof, or metal complex thereof | |
MY160882A (en) | Biocidal composition and method | |
PH12017501404A1 (en) | Diaza-benzofluoranthrene compounds | |
MX2016007985A (es) | Compuestos de fluorofenilpirazol. | |
IN2012DN03343A (es) |